

# Viktar M Mitsura

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2609630/viktar-m-mitsura-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

2,761  
citations

23  
h-index

52  
g-index

75  
ext. papers

3,113  
ext. citations

4.6  
avg, IF

4.13  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 75 | Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , <b>2021</b> , 35, 2025-2033   | 3.9  | 0         |
| 74 | Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 768-776  | 8    | 1         |
| 73 | Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , <b>2021</b> , 22, 283-293  | 2.7  | 2         |
| 72 | Molecular and genetic properties of hepatitis b virus and their clinical role in chronic hepatitis B. <i>HIV Infection and Immunosuppressive Disorders</i> , <b>2021</b> , 12, 43-50  | 0.4  |           |
| 71 | The diagnostic value of indirect markers of liver fibrosis in patients with chronic hepatitis B. <i>Jurnal Infektologii</i> , <b>2020</b> , 12, 73-79   | 0.6  |           |
| 70 | Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1224-1228   | 3.4  | 6         |
| 69 | People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe - data from Euro-guidelines in Central and Eastern Europe Network. <i>Infectious Diseases</i> , <b>2019</b> , 51, 277-286                    | 3.1  | 10        |
| 68 | Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , <b>2019</b> , 20, 264-273  | 2.7  | 7         |
| 67 | Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015. <i>PLoS ONE</i> , <b>2019</b> , 14, e0220108  | 3.7  | 11        |
| 66 | State of viral hepatitis care in 16 countries of Central and Eastern European Region. <i>Central European Journal of Public Health</i> , <b>2019</b> , 27, 212-216  | 1.2  | 1         |
| 65 | Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , <b>2019</b> , 33, 2013-2024   | 3.5  | 11        |
| 64 | Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , <b>2019</b> , 33, 327-337  | 3.5  | 3         |
| 63 | HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , <b>2019</b> , 17, 4   | 11.4 | 27        |
| 62 | Decolonization of Intestinal Carriage of MDR/XDR Gram-Negative Bacteria with Oral Colistin in Patients with Hematological Malignancies: Results of a Randomized Controlled Trial. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2018</b> , 10, e2018030 | 3.2  | 8         |
| 61 | Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , <b>2018</b> , 19, 324-338   | 2.7  | 2         |
| 60 | Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , <b>2018</b> , 21, e25031   | 5.4  | 23        |
| 59 | Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , <b>2018</b> , 19, 252-260  | 2.7  | 1         |

|    |  |      |    |
|----|--|------|----|
| 58 | Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 405-413   | 1.6  | 2  |
| 57 | Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e211-e220                           | 7.8  | 80 |
| 56 | Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 1573-1583   | 4.3  | 22 |
| 55 | Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , <b>2018</b> , 76, 44-54   | 18.9 | 7  |
| 54 | Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , <b>2018</b> , 19, 102-117   | 2.7  | 5  |
| 53 | The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , <b>2018</b> , 19, 90-101  | 2.7  | 8  |
| 52 | HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. <i>HIV Medicine</i> , <b>2018</b> , 19, 629-633 | 2.7  | 4  |
| 51 | Scale-up of HIV self-testing. <i>HIV Medicine</i> , <b>2018</b> , 19, e72  | 2.7  | 6  |
| 50 | Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , <b>2018</b> , 19, 42-48   | 2.7  | 7  |
| 49 | Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , <b>2018</b> , 23,   | 19.8 | 8  |
| 48 | RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS. <i>Jurnal Infektologii</i> , <b>2018</b> , 10, 77-83  | 0.6  | 1  |
| 47 | Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. <i>HIV Medicine</i> , <b>2018</b> , 19, 184-194  | 2.7  | 27 |
| 46 | Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , <b>2018</b> , 32, 161-169   | 3.5  | 14 |
| 45 | Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. <i>HIV Medicine</i> , <b>2018</b> , 19, 132-142  | 2.7  | 6  |
| 44 | Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , <b>2018</b> , 32, 205-215  | 3.5  | 3  |
| 43 | HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. <i>HIV Medicine</i> , <b>2018</b> , 19, 33-41  | 2.7  | 9  |
| 42 | Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , <b>2018</b> , 32, 1995-2004   | 3.5  | 12 |
| 41 | Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, e74-e83   | 3.1  | 16 |

|    |  |      |     |
|----|--|------|-----|
| 40 | Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 1063-1069   | 7    | 18  |
| 39 | Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. <i>HIV Medicine</i> , <b>2017</b> , 18, 370-375  | 2.7  | 11  |
| 38 | Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. <i>HIV Medicine</i> , <b>2017</b> , 18, 33-44   | 2.7  | 10  |
| 37 | One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. <i>Aids</i> , <b>2017</b> , 31, 375-384                       | 3.5  | 1   |
| 36 | Reduction in undiagnosed HIV infection in the European Union/European Economic Area, 2012 to 2016. <i>Eurosurveillance</i> , <b>2017</b> , 22,   | 19.8 | 10  |
| 35 | Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e5020                       | 1.8  | 2   |
| 34 | Infection-related and -unrelated malignancies, HIV and the aging population. <i>HIV Medicine</i> , <b>2016</b> , 17, 590-600   | 2.7  | 31  |
| 33 | Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e120-31  | 7.8  | 42  |
| 32 | Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001809                                   | 11.6 | 107 |
| 31 | Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , <b>2015</b> , 35, 2384-91   | 7.9  | 27  |
| 30 | Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , <b>2015</b> , 16, 533-43  | 2.7  | 9   |
| 29 | Major differences in organization and availability of health care and medicines for HIV/TB coinfecting patients across Europe. <i>HIV Medicine</i> , <b>2015</b> , 16, 544-52  | 2.7  | 15  |
| 28 | Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. <i>Aids</i> , <b>2015</b> , 29, 1205-15   | 3.5  | 37  |
| 27 | Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140845   | 3.7  | 39  |
| 26 | A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , <b>2014</b> , 42, 757-62  | 5.8  | 4   |
| 25 | Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. <i>Aids</i> , <b>2014</b> , 28, 577-87              | 3.5  | 10  |
| 24 | Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , <b>2014</b> , 28, 727-37   | 3.5  | 20  |
| 23 | Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 198104 | 5.4  | 6   |

|    |   |      |     |
|----|---|------|-----|
| 22 | Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 166-77   | 13.6 | 25  |
| 21 | Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. <i>Aids</i> , <b>2014</b> , 28, 2565-71   | 3.5  | 9   |
| 20 | Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. <i>PLoS ONE</i> , <b>2014</b> , 9, e87160  | 3.7  | 28  |
| 19 | Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2013</b> , 17, 198-206                                | 2.1  | 7   |
| 18 | TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , <b>2013</b> , 2013, 373601                                     | 3    | 7   |
| 17 | Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 759-67                    | 7    | 6   |
| 16 | Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , <b>2013</b> , 13, 471  | 4    | 58  |
| 15 | Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfecting patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e64283  | 3.7  | 17  |
| 14 | Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). <i>PLoS ONE</i> , <b>2013</b> , 8, e52845                                     | 3.7  | 111 |
| 13 | Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. <i>PLoS ONE</i> , <b>2012</b> , 7, e41673  | 3.7  | 24  |
| 12 | Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , <b>2012</b> , 26, 1917-26   | 3.5  | 56  |
| 11 | A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 741-52                       | 7    | 16  |
| 10 | Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , <b>2010</b> , 24, 1667-78  | 3.5  | 307 |
| 9  | Dialysis and renal transplantation in HIV-infected patients: a European survey. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 55, 582-9   | 3.1  | 39  |
| 8  | Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, 1138-51 | 11.6 | 90  |
| 7  | Loss to follow-up in an international, multicentre observational study. <i>HIV Medicine</i> , <b>2008</b> , 9, 261-9  | 2.7  | 84  |
| 6  | HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , <b>2008</b> , 22, 2143-53   | 3.5  | 180 |
| 5  | Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , <b>2008</b> , 22, 367-76   | 3.5  | 37  |

|   |   |     |     |
|---|---|-----|-----|
| 4 | Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 46, 607-15 | 3.1 | 37  |
| 3 | Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 1632-41  |     | 869 |
| 2 | Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. <i>HIV Clinical Trials</i> , <b>2006</b> , 7, 271-84                    |     | 5   |
| 1 | Reversible Spatial Filter Of The Type "Photosensitive Organic Polymer - Liquid Crystal" For Holographic Application <b>1990</b> , 1183, 28  |     | 0   |